Multidimensional characterization of motor impairment in distal and myofibrillar myopathies: a multicenter study integrating functional and digital outcome measures
BACKGROUND: Distal and myofibrillar myopathies (DM and MFM) are overlapping groups of muscle diseases. Functional scales often fail to capture distal muscle weakness, hindering patient stratification and trial endpoint selection. This study aims to characterize motor impairment in DM and MFM using functional, digital, and patient-reported outcome measures (PROMs) and to identify functional phenotypes through data-driven clustering. METHODS: In this multicenter study, 51 adults with genetically confirmed DM or MFM (13 genes) underwent a standardized assessment including: Motor Function Measure (MFM32), timed tests, digital dynamometry (MyoTools for distal muscles), and instrumented gait analysis (Loadsol® insoles). PROMs included IBM-FRS and QoL-gNMD. Hierarchical clustering was applied. RESULTS: MFM32 scores were sensitive to the heterogeneity of motor function within the cohort, discriminating among ambulation categories (p<0.001), whereas the distal domain showed a ceiling effect. MyoTools detected distal weakness in over 80% of patients, including those with preserved functional scores. Instrumented gait analysis identified specific alterations in heel strike and foot off phases; heel strike duration correlated with ankle dorsiflexion strength (R=0.67). Cluster analysis identified four functional phenotypes, independent of genetic diagnosis: (1) moderate-to-severe global impairment; (2) anterior compartment predominance; (3) selective lower leg posterior compartment involvement; (4) relatively preserved performance. The IBM-FRS reflected objective motor impairment, while QoL-gNMD highlighted discrepancies between impairment and perceived disease impact. CONCLUSIONS: A multidimensional approach integrating digital measures significantly enhances the characterization of DM and MFM, providing granular data overlooked by traditional scales. Phenotype-based stratification may optimize trial endpoint selection and improve outcome measures sensitivity.
Authors
- Mauro Monforte (ORCID: https://orcid.org/0000-0002-4327-6969)
- Alberto Marzegan (ORCID: https://orcid.org/0000-0002-8389-7655)
- Jean‐Yves Hogrel (ORCID: https://orcid.org/0000-0003-0045-7505)
- Enrica Rolle
- Tiziana Mongini (ORCID: https://orcid.org/0000-0003-4061-4261)
- Sara Bortolani (ORCID: https://orcid.org/0000-0002-6472-0563)
- Alex Vicino (ORCID: https://orcid.org/0000-0001-6420-8124)
- Eleonora Torchia (ORCID: https://orcid.org/0000-0003-1965-6483)
- Giorgio A. Tasca (ORCID: https://orcid.org/0000-0003-0849-9144)
- Sabrina Sacconi (ORCID: https://orcid.org/0000-0002-0246-1455)
- Luísa Villa
- Marco Rabuffetti (ORCID: https://orcid.org/0000-0003-1638-7978)
- Lorenzo Maggi (ORCID: https://orcid.org/0000-0002-0932-5173)
- Giulia Tammam (ORCID: https://orcid.org/0009-0007-4759-5266)
- Enzo Ricci (ORCID: https://orcid.org/0000-0003-3092-3597)
- Riccardo PIOVESAN
- Beatrice Ravera
- V. Trombetta
Institutions
- Università Cattolica del Sacro Cuore (IT)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- Centre Hospitalier Universitaire Vaudois (CH)
- Agostino Gemelli University Polyclinic (IT)
- Centre Hospitalier Universitaire de Nice (FR)
- Institut de Myologie (FR)
- Don Carlo Gnocchi Foundation (IT)
- NIHR Newcastle Biomedical Research Centre (GB)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Fondazione IRCCS Istituto Neurologico Carlo Besta (IT)
- University of Turin (IT)
- Newcastle University (GB)
- University of Lausanne (CH)
Publication Details
- Journal
- Journal of Neurology
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1007/s00415-026-14245-7
- Primary Topic
- Muscle Physiology and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ministero della Salute
- AFM-Téléthon